Clinical trials: Recurrent Glioblastoma Multiforme, open to volunteers
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Recurrent Glioblastoma
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
The clinical study of YSCH-01 will adopt an open-label, randomized design, with a planned enrollment of 10 participants with recurrent glioblastoma.
- Trial name
- NCT07538128
- Testing
- YSCH-01, Atezolizumab (1200 mg every three weeks)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Huashan Hospital
Glioblastoma, Recurrent Disease
Pilot Trial for Treatment of Recurrent Glioblastoma
This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their…
- Conditions
- Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
- Trial name
- NCT05432518
- Testing
- Afatinib, Dasatinib, Palbociclib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma (GBM), Glioblastoma - Category
LITT for Ultra-early GBM Recurrence
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients…
- Trial name
- NCT07616986
- Testing
- LITT
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Recurrent Glioblastoma IDH Wildtype
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced…
- Trial name
- NCT06455605
- Testing
- D2C7-IT, 2141 V11
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Darell Bigner
High Grade Glioma, Glioblastoma
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been…
- Conditions
- High Grade Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT07859059
- Testing
- Dexbrompheniramine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Nebraska
Glioblastoma, High-Grade Gliomas
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups.
- Conditions
- Glioblastoma, High-Grade Gliomas, Grade III Astrocytoma, Grade III Glioma
- Trial name
- NCT06975332
- Testing
- Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
- Where
- 2 sites in Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
Progressive Glioblastoma, Recurrent Glioblastoma
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
This early phase I trial tests the safety, best dose, and effectiveness of SONALA-001 or 5-ALA HCL in combination with magnetic resonance imaging-guided focused ultrasound (MRgFUS), also called sonodynamic therapy, in treating…
- Trial name
- NCT07076472
- Testing
- Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Glioma, Malignant
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain…
- Trial name
- NCT04547777
- Testing
- D2C7-IT, 2141-V11
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Darell Bigner
Glioblastoma
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
The investigational drug 5-ALA (known under the trade name Gliolan®) is an approved drug for the surgical removal of malignant glioma (WHO grade III and IV).
- Trial name
- ALA-RDTinGBM (NCT05590689)
- Testing
- Gliolan, Radiodynamic therapy
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Universität Münster
Recurrent High-Grade Gliomas, Recurrent Glioblastoma IDH Wildtype
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, [177Lu]Lu-DOTA-EB-RGD2, in patients with…
- Trial name
- NCT07655869
- Testing
- [177Lu]Lu-DOTA-EB-RGD2
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Beijing Tiantan Hospital
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Glioblastoma Multiforme of Brain, Glioma
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic…
- Conditions
- Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
- Trial name
- NCT07464925
- Testing
- GLIX1
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tetragon Biosciences Ltd
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT06410248
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Northwestern University
Recurrent Glioblastoma IDH Wildtype
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum…
- Trial name
- NCT07318818
- Testing
- P134 cell injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Glioblastoma Multiforme
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins.
- Trial name
- NCT00083512
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
EGFR Gene Mutation, Glioblastoma
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma.
- Conditions
- EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Trial name
- NCT06186401
- Testing
- E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hideho Okada, MD, PhD
Recurrent Glioblastoma
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
This multicenter, open-label, externally controlled clinical study is designed to evaluate the safety and efficacy of CHANK-101, an autologous natural killer (NK) cell therapy, in patients with recurrent glioblastoma.
- Trial name
- NCT07831161
- Testing
- CHANK-101
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Dong-A University Hospital